The Markey Cancer Center is a diverse matrix enterprise associated with University of Kentucky. Its broad mission is to reduce the morbidity and mortality of cancer through a comprehensive program of cancer research, education, patient care and community outreach.
Markey's research programs span the entire spectrum of cancer epidemiology and etiology, molecular expression and regulation, cancer prevention, early detection and treatment. Associated member scientists include faculty from 28 departments of eight different colleges of University of Kentucky.
Four formal programs are organized to facilitate coordinated efforts in areas of particular breadth and strength. These include:
- Cancer Cell Biology and Signaling
- Cancer Prevention and Control
- Drug Discovery, Delivery and Translational Therapeutics
- Redox Injury and Repair
Markey Cancer Center has particularly strong research and programmatic ties to the UK Colleges of Pharmacy and Public Health, plus the Graduate Center for Toxicology, in addition to all of the oncology departments and divisions of the UK College of Medicine, its primary organizational base.
A principal target of the Markey Cancer Center strategic plan is the
movement of advanced treatments into the mainstream of cancer
management. The MCC Clinical Research Organization facilitates this
process. The Markey Cancer Center is a full-member institute in multiple cooperative clinical trials groups of the National Cancer Institute, including:
- Southwest Oncology Group
- Radiation Therapy Oncology Group
- National Surgical Adjuvant Breast and Bowel Project
- Gynecologic Oncology Group
- Pediatric Oncology Group